Co-Authors
This is a "connection" page, showing publications co-authored by MOTHAFFAR RIMAWI and MEENAKSHI ANURAG.
Connection Strength
0.427
-
Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer. Cancer Discov. 2022 11 02; 12(11):2586-2605.
Score: 0.217
-
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2024 Mar 01; 10(3):362-371.
Score: 0.059
-
Kinase Inhibitor Pulldown Assay Identifies a Chemotherapy Response Signature in Triple-negative Breast Cancer Based on Purine-binding Proteins. Cancer Res Commun. 2023 08; 3(8):1551-1563.
Score: 0.057
-
Immunogenomic?profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer. Breast Cancer Res Treat. 2021 Aug; 189(1):187-202.
Score: 0.049
-
Microscaled proteogenomic methods for precision oncology. Nat Commun. 2020 Jan 27; 11(1):532.
Score: 0.045